Korro Bio (KRRO) CSO reports 25,797 shares after 7,500-share RSU grant
Rhea-AI Filing Summary
Vincent Loic A reported acquisition or exercise transactions in this Form 4 filing.
Korro Bio, Inc. Chief Scientific Officer Vincent Loic A received an equity award covering 7,500 shares of common stock, issuable upon settlement of restricted stock units (RSUs) granted under the 2023 Stock Option and Incentive Plan. These RSUs vest 50% on July 15, 2027 and 50% on July 15, 2028, subject to maintaining a continuous Service Relationship. Following this grant, he reports direct ownership of 25,797 shares, including 18,358 unvested RSU-based shares scheduled to vest 10,858 on December 15, 2026, 3,750 on July 15, 2027, and 3,750 on July 15, 2028.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Vincent Loic A
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 7,500 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 25,797 shares (Direct)
Footnotes (1)
- Represents shares of common stock issuable upon settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan) that will vest as follows: 50% on July 15, 2027 and 50% on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date. Includes 18,358 shares of common stock issuable upon settlement of restricted stock units (RSUs) that remain unvested, consisting of 10,858 shares that will vest on December 15, 2026, 3,750 shares that will vest on July 15, 2027, and 3,750 shares that will vest on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date.
Key Figures
RSU grant size: 7500.0000 shares
Post-transaction holdings: 25797.0000 shares
Unvested RSU-based shares: 18,358 shares
+3 more
6 metrics
RSU grant size
7500.0000 shares
Shares of common stock issuable upon settlement of RSUs granted on July 15, 2026
Post-transaction holdings
25797.0000 shares
Total direct common stock ownership reported after the RSU grant
Unvested RSU-based shares
18,358 shares
Shares of common stock issuable upon settlement of unvested RSUs included in reported holdings
Vesting tranche 1
10,858 shares
Unvested RSU shares scheduled to vest on December 15, 2026
Vesting tranche 2
3,750 shares
Unvested RSU shares scheduled to vest on July 15, 2027
Vesting tranche 3
3,750 shares
Unvested RSU shares scheduled to vest on July 15, 2028
Key Terms
restricted stock unit (RSU), 2023 Stock Option and Incentive Plan, Service Relationship
3 terms
restricted stock unit (RSU) financial
"issuable upon settlement of a restricted stock unit (RSU) granted under the Issuer's 2023"
A restricted stock unit (RSU) is a promise from a company to give an employee company shares (or cash equal to their value) at a future date if certain conditions are met, such as staying with the company or hitting performance targets. For investors, RSUs matter because when they convert into actual shares they increase the number of shares available and can create selling pressure as employees cash out—think of them as a future paycheck paid in company stock.
2023 Stock Option and Incentive Plan financial
"RSU granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan)"
Service Relationship financial
"subject to the reporting person maintaining a continuous Service Relationship through each such date"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What equity award did Korro Bio (KRRO) grant to Vincent Loic A?
Korro Bio granted its Chief Scientific Officer an RSU-based equity award covering 7,500 shares of common stock. These shares are issuable upon settlement of restricted stock units granted under the company’s 2023 Stock Option and Incentive Plan.
When do the newly granted RSUs in Korro Bio (KRRO) vest?
The newly granted RSUs covering 7,500 shares vest in two equal tranches: 50% on July 15, 2027 and 50% on July 15, 2028, in each case subject to maintaining a continuous Service Relationship.
How many unvested RSUs does the Korro Bio (KRRO) CSO have outstanding and what is the schedule?
The Chief Scientific Officer has 18,358 shares of common stock issuable from unvested RSUs. These are scheduled to vest in tranches of 10,858 shares on December 15, 2026, and 3,750 shares on both July 15, 2027 and July 15, 2028.
Under which plan were the latest Korro Bio (KRRO) RSUs granted?
The RSUs relating to 7,500 shares of Korro Bio common stock were granted under the company’s 2023 Stock Option and Incentive Plan, which governs the terms, including vesting and Service Relationship conditions.